Chimerix (NASDAQ:CMRX) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Chimerix (NASDAQ:CMRX) in a research note released on Monday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

A number of other equities research analysts also recently issued reports on the stock. HC Wainwright reaffirmed a “neutral” rating and issued a $8.55 price objective (down from $11.00) on shares of Chimerix in a research report on Wednesday, March 5th. Wedbush reissued a “neutral” rating and issued a $8.55 price target (up from $7.00) on shares of Chimerix in a report on Wednesday, March 5th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and issued a $8.50 price target (down previously from $10.00) on shares of Chimerix in a report on Wednesday, March 5th.

Chimerix Stock Performance

Shares of NASDAQ CMRX opened at $8.51 on Monday. Chimerix has a 52-week low of $0.75 and a 52-week high of $8.53. The company’s 50 day moving average price is $5.94 and its 200-day moving average price is $3.18. The company has a market capitalization of $798.27 million, a P/E ratio of -9.05 and a beta of 0.32.

Chimerix (NASDAQ:CMRX) last issued its quarterly earnings results on Friday, March 21st. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.01. The business had revenue of $0.06 million during the quarter, compared to analyst estimates of $0.31 million. Analysts forecast that Chimerix will post -0.99 earnings per share for the current year.

Insider Buying and Selling

In other Chimerix news, CEO Michael T. Andriole sold 7,370 shares of the business’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total value of $33,312.40. Following the sale, the chief executive officer now directly owns 609,603 shares of the company’s stock, valued at approximately $2,755,405.56. The trade was a 1.19 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have sold a total of 20,760 shares of company stock valued at $91,175 over the last ninety days. Company insiders own 13.10% of the company’s stock.

Institutional Trading of Chimerix

Large investors have recently made changes to their positions in the stock. Squarepoint Ops LLC bought a new stake in shares of Chimerix during the 4th quarter valued at about $130,000. Two Sigma Investments LP lifted its position in shares of Chimerix by 309.1% during the 4th quarter. Two Sigma Investments LP now owns 101,156 shares of the biopharmaceutical company’s stock valued at $352,000 after buying an additional 76,430 shares in the last quarter. OMERS ADMINISTRATION Corp purchased a new stake in Chimerix in the 4th quarter worth approximately $535,000. Millennium Management LLC raised its stake in Chimerix by 6.8% during the 4th quarter. Millennium Management LLC now owns 2,557,530 shares of the biopharmaceutical company’s stock worth $8,900,000 after acquiring an additional 161,795 shares during the period. Finally, Deerfield Management Company L.P. Series C purchased a new position in Chimerix during the fourth quarter valued at approximately $13,124,000. 45.42% of the stock is currently owned by institutional investors.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.